More than 125 million people worldwide suffer from some form of psoriasis. If you’ve struggled with your skin health this ...

Dublin, Jan. 23, 2025 (GLOBE NEWSWIRE) -- The "Plaque Psoriasis Market by Treatment, by Route of Administration, by End-user, and by Region" report has been added to ResearchAndMarkets.com's offering.

Plaque psoriasis, the most common form of psoriasis, is a type of autoimmune condition where the body’s immune cells attack its own healthy cells. Bimzelx was approved for the treatment of ...

However, most treatment guidelines were developed based ... Asian consensus on assessment and management of mild to moderate plaque psoriasis with topical therapy. J Dermatol.

Dallas Goedert details how the team's victory in Super Bowl LIX is even "more sweet" considering what the Eagles went through ...

Now, six months into the NSW Pharmacy Dermatology Trial, pharmacists are now also appropriately trained to manage impetigo ...

Akeso, Inc. (9926.HK) ('Akeso' or the 'Company') is pleased to announce that the New Drug Application (NDA) of its internally-developed IL-17-targeting monoclonal antibody gumokimab (AK111) has been ...

Before your next plaque surfaces and that unbearable tingle of an itch ... explained that salicylic acid is a beta hydroxy acid commonly found in topical psoriasis treatments and can be helpful for ...

Yahoo Sports’ Caroline Fenton spoke with the Philadelphia Eagles tight end about the team’s championship win, his quarterback ...

The following is a summary of “Bimekizumab efficacy and safety through 3 years in patients with moderate to severe plaque psoriasis: Long-term results from the BE RADIANT phase 3b trial open-label ...

Deucravacitinib significantly improved skin-related quality of life of patients with moderate to severe plaque psoriasis, according to a poster presented at Maui Derm Hawaii 2025. A total of 40.6% to ...

Real‐world effectiveness and safety of tildrakizumab in long‐term treatment of plaque psoriasis: Results from the non‐interventional, prospective, multicentre study TILOT. J Eur Acad ...